The Pediatric Cancer Biomarker Market was valued at USD 830.41 Million in 2023 and is projected to reach USD 1635.68 Million by 2032 with a growing CAGR of 7.84% over the forecast period of 2024-2032.
This report emphasizes the growing incidence and prevalence of pediatric cancer, driving demand for sophisticated diagnostic technologies, including biomarkers. The research identifies trends in the use of biomarkers across regions, highlighting early detection and personalization of treatment. It also analyzes R&D spending and funding trends, identifying contributions from government programs, private institutions, and commercial players toward developing biomarkers. The regulatory environment and approval procedures for pediatric cancer biomarkers are also evaluated, as they affect market growth and availability. In addition, the report explores the increasing importance of companion diagnostics and personalized medicine in pediatric oncology, highlighting how biomarker-guided strategies are revolutionizing treatment outcomes and precision care.
Drivers
Increasing incidences of pediatric cancers, advancements in personalized medicine, and technological innovations in diagnostic tools
Based on the American Cancer Society, almost 10,500 children below 15 years are diagnosed with cancer each year in the United States alone, of which leukemia and brain tumors are the most frequent. This increasing incidence of childhood cancer directly enhances the demand for early and precise diagnostic devices, specifically biomarkers that can offer details regarding the genetic makeup of the tumor, crucial for tailored treatment. In addition, the use of liquid biopsy technologies such as NGS (Next-Generation Sequencing) and proteomics is enhancing pediatric cancer diagnostic precision. Targeted therapy and immunotherapy research also propels market growth since the former depends on the identification of certain biomarkers to effectively use them. Investments by government and healthcare in pediatric oncology research, for example, National Cancer Institute (NCI) funding and those by the European Union, also drive the growth of the market. Rising awareness among parents and medical professionals about pediatric cancer also fuels early detection and a larger demand for solutions based on biomarkers.
Restraints
The high costs of pediatric cancer biomarker testing and limited accessibility remain major restraints for the market.
The expense of high-diagnostics tests like liquid biopsies and genetic sequencing is out of reach for most families and healthcare systems. For instance, NGS-based tests may vary from USD 1,000 to USD 10,000 based on the level of complexity of the testing involved, which may not be accessible to uninsured patients or in public healthcare systems in developing nations. This cost restricts the mass usage of these technologies, especially in poor areas. In addition, the absence of skilled staff and healthcare facilities to conduct these sophisticated tests in some areas of the globe worsens the situation. The unequal resource and expertise allocation between developed and developing countries contributes to huge imbalances in access to state-of-the-art diagnostics. Moreover, the new biomarker tests' regulatory approval process is lengthy and costly, further contributing to the difficulties in diagnostic companies providing wider access to these life-saving technologies worldwide. Unless there is a concerted effort to reduce the costs, make them more accessible, and eliminate the complexity in regulatory approvals, these will still be the main inhibitors of the market's potential.
Opportunities
The growing interest in liquid biopsy and targeted therapies presents substantial opportunities for the pediatric cancer biomarker market.
Liquid biopsy, which tests blood samples for tumor RNA or DNA, provides a non-invasive, inexpensive alternative to standard tissue biopsies and is especially valuable for pediatric patients who are likely to have complications with invasive testing. With the advancement of technology, liquid biopsy will change the face of early detection, monitoring, and treatment response assessment in pediatric cancer. Besides this, the rise in interest in precision medicine and the discovery of targeted therapies in response to selected genetic mutations or biomarkers of pediatric cancers has tremendous growth opportunities. For example, the ALK inhibitors applied to neuroblastoma and the CD19-directed CAR-T cells used in leukemia have yielded impressive outcomes. An illustration of such an outcome following precision medicine depending on biomarkers is the FDA-approved Kymriah in pediatric leukemia. Pediatric oncology biomarker research and development are being strongly supported by pharma firms and biotech companies, which are breaking new grounds for novel therapies. In addition, the cooperation among academic institutions, biotech companies, and pharma companies is resulting in the identification of new biomarkers, thereby paving the way for new diagnostic technologies and therapies for pediatric cancers. Such cooperation among different stakeholders is important for driving future growth.
Challenges
The regulatory hurdles associated with the approval and commercialization of new diagnostic tests and treatments.
The FDA's process of approval for new biomarkers usually consists of large-scale clinical trials and data gathering that takes years and costs a great deal. The pediatric population has its special regulatory challenges in that treatment and diagnostic agents need to be particularly tested and reformulated for children, which is distinct from research on adult oncology. The protracted approval times and complexity of regulation requirements across regions have the potential to slow the deployment of life-saving technologies. Another hurdle is the data integration problem, as more genetic and molecular information becomes available using newer diagnostic tools such as NGS and multi-omics, physicians find it challenging to process this information quickly, interpret it, and integrate it into clinical decision-making. The absence of standardized methods for interpreting biomarker data can result in inconsistent results, diluting the utility of tailored treatment strategies. Additionally, concerns about patient privacy and data security in managing patient data complicate the use of digital technology in pediatric cancer biomarker screening. These constraints call for improved regulatory environments, more transparent data-sharing mechanisms, and cooperation among stakeholders to overcome challenges and unlock the full potential of pediatric cancer biomarkers.
By Indication
In 2023, the leukemia segment held the largest share in the pediatric cancer biomarker market at 41.2% of the overall market share. Leukemia, especially acute lymphoblastic leukemia (ALL), is the leading childhood cancer, and this fuels a high need for biomarker-based diagnostics. CD19, CD22, and minimal residual disease (MRD) markers are some of the biomarkers that have become essential in monitoring the disease, risk stratification, and treatment planning. The growing acceptance of CAR-T cell therapy and targeted therapies that need biomarker-based companion diagnostics has further bolstered leukemia's leadership in the market. In addition, development in flow cytometry, next-generation sequencing (NGS), and polymerase chain reaction (PCR) methodologies has enhanced the early detection and tailored treatment methods. Increased consciousness of precision medicine and an increase in pediatric cancer screening programs among hospitals and research centers have also been key drivers for the robust market presence of this segment.
The CNS tumors segment is growing at the highest rate owing to increasing incidences of pediatric brain and central nervous system tumors and rising investments in biomarker-based diagnostics. The advent of molecular biomarkers such as DNA methylation profiling, cerebrospinal fluid-based liquid biopsies, and NGS-based tests has improved early diagnosis and treatment planning. Moreover, clinical trials of targeted therapies for specific genetic alterations in CNS tumors are driving market growth.
By Biomarker
The CD19, CD20, and CD22 biomarker segments dominated the market in 2023, capturing 30.1% of the overall share, owing mainly to its application in diagnosing and treating pediatric lymphoma and leukemia. The biomarkers are extensively used in immunophenotyping, risk stratification, and minimal residual disease (MRD) monitoring in children. The rising use of CD-targeted immunotherapies, especially CAR-T cell therapies like Kymriah and Tecartus, has also increased their clinical demand further. Additionally, diagnostic laboratories and hospitals are incorporating new technologies like flow cytometry, fluorescence in situ hybridization (FISH), and enzyme-linked immunosorbent assays (ELISA) to enhance the efficiency of biomarker-based testing. The increasing application of targeted therapies and monoclonal antibodies has further cemented the supremacy of biomarkers in pediatric cancer diagnosis.
The ALK (anaplastic lymphoma receptor tyrosine kinase gene) segment is experiencing the highest growth with its increasingly recognized role in pediatric lymphomas and neuroblastoma. Oncogenic drivers in the form of ALK mutations and rearrangements have been recognized, and therefore, are crucial for precision medicine interventions. The increasing use of ALK inhibitors like Crizotinib and Lorlatinib, together with more clinical trials for targeted therapy, have driven market growth. The improvements in liquid biopsy and genomic profiling have also increased the adoption of ALK biomarker testing.
By End Use
The hospital segment contributed the highest share of 41.2% in 2023, as hospitals are still the main centers for pediatric cancer diagnosis, treatment, and biomarker testing. Hospitals contain sophisticated diagnostic equipment, allowing the application of molecular diagnostics, flow cytometry, and genetic sequencing to identify cancer biomarkers effectively. With the growing focus on precision medicine, hospitals are incorporating biomarker-guided strategies into treatment protocols for better patient outcomes. Moreover, government programs and reimbursement policies have facilitated the extensive application of biomarker-based diagnostics in hospitals. The availability of multidisciplinary oncology teams, pediatric specialists, and the capability to perform biopsy-based and liquid biopsy testing have also strengthened the leadership of hospitals in the pediatric cancer biomarker market.
The research institutions segment is the most rapidly growing segment owing to increased investments in biomarker discovery, precision oncology, and pediatric cancer research. Research centers are at the forefront of creating new biomarkers, resulting in new diagnostic devices, targeted therapies, and AI-based biomarker analysis. Growing funding from government grants, private investors, and pharma companies is driving research into multi-omics strategies like genomics, proteomics, and metabolomics. Further, CRISPR gene-editing advances, machine learning for biomarker discovery, and real-time monitoring technologies are widening the scope of biomarkers in pediatric cancer diagnosis.
North America dominated the pediatric cancer biomarker market in 2023 with the highest share, driven by its well-developed healthcare infrastructure, extensive use of innovative biomarker diagnostics, and heavy investments in pediatric oncology research. The United States is a key contributor, with leading healthcare providers and research centers heavily investing in the development of pediatric cancer biomarkers. Its dominance of the regional market is supplemented by having dominant pharmaceutical and diagnostic companies present within, boosting its ranking as the global leader in the same area.
At the same time, Europe's market is experiencing steady development, fueled by strong healthcare infrastructure, government support, and a developing focus on personalized medicine. The UK, Germany, and France are the leaders in applying biomarker-driven diagnostics to pediatric cancer, and research institutions have been instrumental in pushing biomarker discovery and clinical utility forward.
The Asia-Pacific market is set to witness high growth in the market, driven by enhanced access to healthcare, growing awareness of pediatric cancer, and rising government expenditure on medical research. Major nations such as China, India, and Japan are becoming major contributors, with growing healthcare investments and advancements in molecular diagnostics. This is likely to further drive the market growth in the region.
F. Hoffmann-La Roche Ltd – Cobas EGFR Mutation Test, FoundationOne Liquid
Abbott Laboratories – Vysis ALK Break Apart FISH Probe Kit, RealTime IDH1 Assay
Siemens Healthineers – ADVIA Centaur AFP Assay, IMMULITE Tumor Marker Assays
Thermo Fisher Scientific Inc. – Oncomine Childhood Cancer Research Assay, Ion AmpliSeq Panels
QIAGEN N.V. – QIAseq Targeted DNA Panels, ipsogen JAK2 RGQ PCR Kit
Myriad Genetics, Inc. – MyRisk Hereditary Cancer Test
Beckman Coulter, Inc. – Access AFP Assay, Flow Cytometry Panels
Bio-Rad Laboratories, Inc. – Bio-Plex Pro Cancer Biomarker Panels
Agilent Technologies, Inc. – SureSelect Cancer All-In-One Panels, ALK FISH Probe
BIOMÉRIEUX SA. – VIDAS Tumor Markers, NephroCheck Biomarker Test
RayBiotech, Inc. – Human Cancer Biomarker Array, ELISA Kits for Oncology
Randox Laboratories Ltd. – Evidence Investigator Tumor Marker Array, Biochip Technology
Illumina, Inc. – TruSight Oncology 500, NGS Panels for Pediatric Cancer
AstraZeneca PLC – Companion Diagnostics for Targeted Therapies
Guardant Health, Inc. – Guardant360 CDx Liquid Biopsy
ICON Public Limited Company – Biomarker Discovery & Validation Services
Merck Sharp & Dohme Corp. – Oncology Biomarker Partnerships
In Feb 2025, Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital committed USD 1.8 million to advance childhood cancer research, supporting innovative studies focused on improving diagnostics and treatments.
In Jan 2025, UK HealthCare earned Pediatric Specialty Accreditation from the American College of Surgeons (ACS) Commission on Cancer (CoC), recognizing its high standards in pediatric cancer care. This accreditation highlights its excellence in treating children and adolescents with cancer.
| Report Attributes | Details |
|---|---|
|
Market Size in 2023 |
USD 830.41 Million |
|
Market Size by 2032 |
USD 1635.68 Million |
|
CAGR |
CAGR of 7.84% From 2024 to 2032 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2032 |
|
Historical Data |
2020-2022 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
• By Indication [Leukemia, Neuroblastoma, CNS Tumors, Lymphoma, Others] |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
|
Company Profiles |
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific Inc., QIAGEN N.V., Myriad Genetics, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., BIOMÉRIEUX SA, RayBiotech, Inc., Randox Laboratories Ltd., Illumina, Inc., AstraZeneca PLC, Guardant Health, Inc., ICON Public Limited Company, Merck Sharp & Dohme Corp. |
Ans: The Pediatric Cancer Biomarker market is projected to grow at a CAGR of 7.84% during the forecast period.
Ans: By 2032, the Pediatric Cancer Biomarker market is expected to reach USD 1635.68 Million, up from USD 830.41 Million in 2023.
Ans: Increasing incidences of pediatric cancers, advancements in personalized medicine, and technological innovations in diagnostic tools
Ans: The high costs of pediatric cancer biomarker testing and limited accessibility remain major restraints for the market.
Ans: North America is the dominant region in the Pediatric Cancer Biomarker market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Pediatric Cancer (2023)
5.2 Biomarker Utilization Trends in Pediatric Cancer (2023), by Region
5.3 R&D Investment and Funding Trends, by Region (Government, Commercial, Private, Grants), 2023
5.4 Regulatory Landscape and Approvals for Pediatric Cancer Biomarkers (2023)
5.5 Companion Diagnostics and Personalized Medicine Trends in Pediatric Oncology
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Pediatric Cancer Biomarker Market Segmentation, by Indication
7.1 Chapter Overview
7.2 Leukemia
7.2.1 Leukemia Market Trends Analysis (2020-2032)
7.2.2 Leukemia Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Neuroblastoma
7.3.1 Neuroblastoma Market Trends Analysis (2020-2032)
7.3.2 Neuroblastoma Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 CNS Tumors
7.4.1 CNS Tumors Market Trends Analysis (2020-2032)
7.4.2 CNS Tumors Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Lymphoma
7.5.1 Lymphoma Market Trends Analysis (2020-2032)
7.5.2 Lymphoma Market Size Estimates and Forecasts to 2032 (USD Million)
7.6 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8. Pediatric Cancer Biomarker Market Segmentation, by Biomarker
8.1 Chapter Overview
8.2 Alpha-fetoprotein (AFP)
8.2.1 Alpha-fetoprotein (AFP) Market Trends Analysis (2020-2032)
8.2.2 Alpha-fetoprotein (AFP) Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Neuron-specific enolase (NSE)
8.3.1 Neuron-specific enolase (NSE) Market Trends Analysis (2020-2032)
8.3.2 Neuron-specific enolase (NSE) Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 CD19, CD20, CD22
8.4.1 CD19, CD20, CD22 Market Trends Analysis (2020-2032)
8.4.2 CD19, CD20, CD22 Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 ALK (anaplastic lymphoma receptor tyrosine kinase gene)
8.5.1 ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Trends Analysis (2020-2032)
8.5.2 ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Others
8.6.1 Others Market Trends Analysis (2020-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Pediatric Cancer Biomarker Market Segmentation, by End-Use
9.1 Chapter Overview
9.2 Hospital
9.2.1 Hospital Market Trends Analysis (2020-2032)
9.2.2 Hospital Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Diagnostic Laboratories
9.3.1 Diagnostic Laboratories Market Trends Analysis (2020-2032)
9.3.2 Diagnostic Laboratories Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Oncology Centers
9.4.1 Oncology Centers Market Trends Analysis (2020-2032)
9.4.2 Oncology Centers Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Research Institutions
9.5.1 Research Institutions Market Trends Analysis (2020-2032)
9.5.2 Research Institutions Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.4 North America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.2.5 North America Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.6.2 USA Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.2.6.3 USA Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.7.2 Canada Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.2.7.3 Canada Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.8.2 Mexico Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.2.8.3 Mexico Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.6.2 Poland Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.1.6.3 Poland Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.7.2 Romania Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.1.7.3 Romania Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.8.2 Hungary Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.1.8.3 Hungary Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.9.2 Turkey Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.1.9.3 Turkey Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.4 Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.5 Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.6.2 Germany Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.6.3 Germany Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.7.2 France Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.7.3 France Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.8.2 UK Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.8.3 UK Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.9.2 Italy Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.9.3 Italy Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.10.2 Spain Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.10.3 Spain Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.13.2 Austria Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.13.3 Austria Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.4 Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.5 Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.6.2 China Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.6.3 China Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.7.2 India Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.7.3 India Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.8.2 Japan Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.8.3 Japan Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.9.2 South Korea Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.9.3 South Korea Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.10.2 Vietnam Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.10.3 Vietnam Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.11.2 Singapore Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.11.3 Singapore Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.12.2 Australia Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.12.3 Australia Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.4 Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.1.5 Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.6.2 UAE Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.1.6.3 UAE Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.7.2 Egypt Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.1.7.3 Egypt Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.9.2 Qatar Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.1.9.3 Qatar Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.4 Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.2.5 Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.6.2 South Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.2.6.3 South Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.4 Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.6.5 Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.6.2 Brazil Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.6.6.3 Brazil Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.7.2 Argentina Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.6.7.3 Argentina Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.8.2 Colombia Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.6.8.3 Colombia Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by Biomarker (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Pediatric Cancer Biomarker Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 Abbott Laboratories
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Siemens Healthineers
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Thermo Fisher Scientific Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 QIAGEN N.V.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 BIOMÉRIEUX SA
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Randox Laboratories Ltd.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 Illumina, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 AstraZeneca PLC
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Merck Sharp & Dohme Corp.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Indication
Leukemia
Neuroblastoma
CNS Tumors
Lymphoma
Others
By Biomarker
Alpha-fetoprotein (AFP)
Neuron-specific enolase (NSE)
CD19, CD20, CD22
ALK (anaplastic lymphoma receptor tyrosine kinase gene)
Others
By End Use
Hospital
Diagnostic Laboratories
Oncology Centers
Research Institutions
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Chlamydia Infection Treatment Market Size was valued at USD 3.83 billion in 2023, and is expected to reach USD 8.89 billion by 2032, and grow at a CAGR of 9.81% over the forecast period 2024-2032.
The Soft Tissue Allograft Market size was valued at USD 5.11 billion in 2023 and is expected to reach USD 8.46 billion by 2032, with a growing at CAGR of 5.77% over the forecast period of 2024-2032.
The Cognitive Behavioral Therapy Market Size was valued at USD 6.69 Billion in 2023, and is expected to reach USD 25.27 Billion by 2032, and grow at a CAGR of 16.81%.
The Injection Pen Market was valued at USD 40.6 billion in 2023 and is projected to reach USD 73.8 billion by 2032, with a growing CAGR of 6.8% from 2024 to 2032.
The Digital Clinical Trials Market was valued at USD 8.70 Bn in 2023 and is expected to reach at $13.86 Bn in 2031 and grow at a CAGR of 6 % by 2024-2031.
7T Magnetic Resonance Imaging Systems Market was valued at USD 2.01 billion in 2023 and is expected to reach USD 3.78 billion by 2032, growing at a CAGR of 7.26% from 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
